Menu Search
Equities

Madrigal Pharmaceuticals Inc

YDO1:DEU

Madrigal Pharmaceuticals Inc

Actions
  • Price (EUR)311.60
  • Today's Change12.90 / 4.32%
  • Shares traded112.00
  • 1 Year change+81.80%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

  • Revenue in USD (TTM)76.81m
  • Net income in USD-518.67m
  • Incorporated2000
  • Employees376.00
  • Location
    Madrigal Pharmaceuticals Inc200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN 19428-2978United StatesUSA
  • Phone+1 (404) 380-9263
  • Fax+1 (302) 655-5049
  • Websitehttps://www.madrigalpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.